International journal of immunology and immunotherapy最新文献

Using an Antagonist of Chimeric Receptor Antigen T Cell Therapy to Prevent Cytokine Storm in COVID-19: A Hypothesis 使用嵌合受体抗原T细胞拮抗剂治疗COVID-19预防细胞因子风暴:一个假设

International journal of immunology and immunotherapy Pub Date : 2023-12-31 DOI: 10.23937/2378-3672/1410068

Ngokwe Zilefac Brian, Fokam Tamoh Stive, Bienvenue NtepNtep David, Stephane Nokam Kamdem, Fon Cheboh Cho, Audrey Kouamou Tchiekou, Macbrain Elage Epie, Arthur Tamgnoue Guillaume

{"title":"Using an Antagonist of Chimeric Receptor Antigen T Cell Therapy to Prevent Cytokine Storm in COVID-19: A Hypothesis","authors":"Ngokwe Zilefac Brian, Fokam Tamoh Stive, Bienvenue NtepNtep David, Stephane Nokam Kamdem, Fon Cheboh Cho, Audrey Kouamou Tchiekou, Macbrain Elage Epie, Arthur Tamgnoue Guillaume","doi":"10.23937/2378-3672/1410068","DOIUrl":"https://doi.org/10.23937/2378-3672/1410068","url":null,"abstract":"SARS-COV-2 pandemic is almost 3-years-old and remains a case for concern. An overwhelming production of pro-inflammatory cytokines in the context of COVID-19, not only impairs viral clearance but also promotes paradoxically hyperinflammation including cytokine storm; an unfortunate event leading to organ failure following long term damage due to inflammation and even death. With the advent of new variants, the interaction between vaccinated and unvaccinated people and also the interaction between persons with different variants or between the healthy and the asymptomatic; all of these possibly leading to the formation of new variants. CAR T therapy has achieved remarkable clinical results treatment of relapsed/refractory B-cell-derived malignancies. CAR T and SARS-COV-2 share one thing in common; the cytokine storm even though the former is a treatment associated complication and the latter is an exaggerated host response. Hence, we propose using Immunopharmacology (which targets amongst others, pathologies in which inflammation is the main component), by using anti-CAR-engineered T to target the cytokine storm in COVID-19 with objective to help alleviate these symptoms or as a possible solution. Specifically, by using T lymphocytes as living drugs equipped with a CAR construct directed against TH2 or viral epitopes. We hope to curb the severe complications and the poor outcomes (mortalities) associated with this pathology.","PeriodicalId":92912,"journal":{"name":"International journal of immunology and immunotherapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68748327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Variability of Immune Biomarkers with the Graft Function in Kidney Transplant Patients in India, an Observational Prospective Cohort Study 印度肾移植患者免疫生物标志物与移植物功能的可变性，一项观察性前瞻性队列研究

International journal of immunology and immunotherapy Pub Date : 2023-09-14 DOI: 10.11648/j.iji.20231101.12

Bejugama Katyayani, Guditi Swarnalatha, Taduri Gangadhar

{"title":"Variability of Immune Biomarkers with the Graft Function in Kidney Transplant Patients in India, an Observational Prospective Cohort Study","authors":"Bejugama Katyayani, Guditi Swarnalatha, Taduri Gangadhar","doi":"10.11648/j.iji.20231101.12","DOIUrl":"https://doi.org/10.11648/j.iji.20231101.12","url":null,"abstract":"In renal transplantation (RT), the major issue is to maintain the immune homeostasis, limiting graft rejection (GR), and promoting transplant tolerance. A total of 70 subjects of chronic kidney disease patients on maintenance haemodialysis, opted for RT and 20 controls were recruited. The Tregs% (CD4+CD25+), concentration of cytokines IL –10 and IL 17 were measured in pre-and post-transplant at a defined timelines with stable graft function (SGF) and with GR for two years, using flow cytometer and sandwich ELISA method. With SGF, Tregs% Baseline [8.5 (6.5–10.7) vs. HCs [14.25 (13–18), p < 0.01)], at Baseline vs. six months [11.54 (8.9–15)], p < 0.001); At Baseline [3.05 (1.05–5.2) vs. GR 8.5 (6.5–10.7), p < 0.05]. Serum IL 10 baseline [3.6 (2.56–4.6) vs. HC (6.4 (4.8-9.8), p<0.001]. Serum IL 17 levels at baseline [120 (92 - 176) vs. HC [20.88 (18-55), p<0.05], day four vs. baseline [180 (160.5-257.45); p<0.05], day 90 vs. baseline [53.3 (48-100), p< 0.05] and this was maintained for two years, with GR vs. baseline [190 (105-372); p<0.05]. ROC analysis of Tregs% (AUC of 0.758 and a p – value of <0.05), IL-10 (AUC of 0.8 and a p – value of 0.117), IL-17 (AUC of 0.937 and a p – value of <0.05). With SGF, Tregs % increased from 6 months, IL-17 decreased from 3 months, IL-10 did not show changes and continued till two years; with GR, Tregs% decreased from baseline, IL-10 did not show changes, and IL-17 increased due to high inflammation. ROC analysis showed that the Tregs% and IL-17 are better predictors of graft outcome. However, the association between biomarkers with graft function couldn’t be evaluated which needs further studies.","PeriodicalId":92912,"journal":{"name":"International journal of immunology and immunotherapy","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134971404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative Evaluation of the ID NOWTM Test (Abott) and RT-PCR for the Detection of the SARS-CoV-2 Genome in Travellers ID NOWTM旅行者SARS-CoV-2基因组检测的abtt法和RT-PCR

International journal of immunology and immunotherapy Pub Date : 2023-09-14 DOI: 10.11648/j.iji.20231102.11

Ndao Malick, Diagne Babacar, Diagne Rokhaya, Niane Moustapha, Ka Roughyatou

{"title":"Comparative Evaluation of the ID NOW&lt;SUP&gt;TM&lt;/SUP&gt; Test (Abott) and RT-PCR for the Detection of the SARS-CoV-2 Genome in Travellers","authors":"Ndao Malick, Diagne Babacar, Diagne Rokhaya, Niane Moustapha, Ka Roughyatou","doi":"10.11648/j.iji.20231102.11","DOIUrl":"https://doi.org/10.11648/j.iji.20231102.11","url":null,"abstract":"Introduction: The persistence of the COVID-19 pandemic, which has become a global public health problem, means that the implementation of effective and affordable diagnostic strategies is essential, particularly in developing countries, to contain the disease. Rapid, reliable and inexpensive molecular or antigenic tests enable early detection of cases and rapid clinical management. The method based on reverse transcription-polymerase chain reaction (RT-PCR) is the benchmark for diagnosing SARS-CoV-2 infections. However, this method requires highly qualified human resources, complex equipment, consumables and reagents that are usually expensive and imported from developed countries. Given these technical and financial constraints and the limited capacity of molecular platforms in developing countries, point-of-care can be considered a very good alternative. The aim of this study was to evaluate the performance of the ID NOWTM COVID-19 test for the detection of SARS-COV-2 from nasopharyngeal swab samples collected in tubes containing viral transport medium compared with RT-PCR. Method: The evaluation was carried out on 59 travellers from whom a nasopharyngeal swab was taken in 3 ml of viral transport medium (VTM). A swab from the ID-NOW kit was dipped into each sample and then deposited in the sample recipient in order to assess the performance of the ID-NOW test compared with RT-PCR. Results: In our study, we found a sensitivity of 92.6% (23/25) and a specificity of 100%. However, 2 false negatives were found with samples that had CT values of 36. No cross-contamination between samples was observed in this study. Conclusion: Our data showed that the ID NOWTM COVID-19 test would be an excellent tool for screening suspected cases in clinical departments.","PeriodicalId":92912,"journal":{"name":"International journal of immunology and immunotherapy","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134971438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association Between ABO-RHD Blood Groups and COVID-19: A Preliminary Study of 76 Cases ABO-RHD血型与76例COVID-19相关性的初步研究

International journal of immunology and immunotherapy Pub Date : 2023-05-10 DOI: 10.11648/j.iji.20231101.11

Adou Adjoumanvoule Honore, Siransy Kouabla Liliane, Memel Lasme Roselle Charline, Yeboah Oppong Richard, Goran-Kouacou Amah Patricia, Kone Djakaridja, Kadiane-Oussou N'dri Juliette, Assi Aya Ursule Aniela, Gnemagnon Mahi Eric Constant, Ouattara Awa, Oura Brou Doris, Moussa Sali, Koya Hebert Gautier, Seri Yida Jocelyne, Aba Yapo Thomas, Kra Ouffoue

{"title":"Association Between ABO-RHD Blood Groups and COVID-19: A Preliminary Study of 76 Cases","authors":"Adou Adjoumanvoule Honore, Siransy Kouabla Liliane, Memel Lasme Roselle Charline, Yeboah Oppong Richard, Goran-Kouacou Amah Patricia, Kone Djakaridja, Kadiane-Oussou N'dri Juliette, Assi Aya Ursule Aniela, Gnemagnon Mahi Eric Constant, Ouattara Awa, Oura Brou Doris, Moussa Sali, Koya Hebert Gautier, Seri Yida Jocelyne, Aba Yapo Thomas, Kra Ouffoue","doi":"10.11648/j.iji.20231101.11","DOIUrl":"https://doi.org/10.11648/j.iji.20231101.11","url":null,"abstract":": Introduction: Blood types are most often incriminated in susceptibility to COVID-19. Blood group O subjects are reportedly less susceptible to COVID-19. However, these reports are mainly from countries with high infection rates. The overall objective of this study was to investigate the association between the risk of COVID-19 infection, its severity, and ABO-RHD blood groups at the Training Hospitals of Bouake and Cocody (Ivory Coast). Material and methods: This was a prospective study that lasted four months. All patients with COVID-19 at the time of the study and followed at the Training Hospitals of Bouake and Cocody, hospitalized in the COVID-19 centers or in home confinement, were included. T lymphocyte subpopulations were counted on the BD FACS Calibur flow cytometer after labeling. ABO and RHD blood typing was performed in all patients. Results: Of the 76 patients collected, 78.9% were homebound, 18.4% in hospital and 2.6% in the ICU. The mean age was 41.92 ± 15.13 years with a male predominance. The majority of hospitalized patients were significantly of blood group A (p=0.020). CD4 and CD8 T lymphopenia were significantly more frequent in patients with blood group A than in those with blood groups B, AB and O. Conclusion: The impact of blood group on the severity of the disease would exist. Our study showed that blood group A subjects were more likely to have COVID-19. In addition, a statistically significant association between blood type A and CD4 and CD8 T lymphopenia was found. These results should be confirmed by studies based on larger patient samples.","PeriodicalId":92912,"journal":{"name":"International journal of immunology and immunotherapy","volume":"102 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83921104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent Application of Nanotechnology for Cancer Immunotherapy and Its Future Prospects 纳米技术在肿瘤免疫治疗中的最新应用及展望

International journal of immunology and immunotherapy Pub Date : 2023-01-01 DOI: 10.23937/2378-3672/1410069

Akabari Ashok H, Patel Sagarkumar, Vaghela Nikita, Ramani Vinod, Shah Dhiren P

引用次数: 0

Evaluation of Some Inflammatory Cytokines Levels as A Marker for Diabetes 一些炎性细胞因子水平作为糖尿病标志物的评估

International journal of immunology and immunotherapy Pub Date : 2022-12-31 DOI: 10.23937/2378-3672/1410065

Abo-Zaid Mabrouk A, Mohammed Soha S, I. Ahmed H.

{"title":"Evaluation of Some Inflammatory Cytokines Levels as A Marker for Diabetes","authors":"Abo-Zaid Mabrouk A, Mohammed Soha S, I. Ahmed H.","doi":"10.23937/2378-3672/1410065","DOIUrl":"https://doi.org/10.23937/2378-3672/1410065","url":null,"abstract":"From the different causes of death diabetes has an advanced rank in the first 10. So the aim of this study was to relate between some pro-inflammatory cytokines (TNF-α, IL-6, and TGF-β1) and infection with diabetes as biomarkers for infection. Forty male Wister albino Streptozotocin (STZ) induced diabetic rats were used as a model for estimation of the related cytokines. The animals were divided in two groups, the first group was given a placebo, whereas the second was given Streptozotocin at a single dose of 70 mg/kg body weight to induce diabetes mellitus. Each rat's blood glucose level was measured 72 hours later. Diabetes was successfully induced in rats with blood glucose levels greater than 300 mg/dl. After 7 days, all groups were sacrificed and immunological responses, tumor necrosis factor-alpha (TNF-α), interleukin (IL-6), and transforming growth factor (TGF-β1) were measured. Glucose levels were shown to be significantly higher in the group that was given Streptozotocin at a single dose of 70 mg/kg body weight, with a percent change of 217.5% when compared to the control group. While in the diabetic group, there was also a large increase in IL-6, TNF-α and TGF-β1 levels, with a percent change of 82.24%, 77.7% and 74.5% respectively. From these results we can recommend these cytokines as a biomarkers for diabetes mellitus disease.","PeriodicalId":92912,"journal":{"name":"International journal of immunology and immunotherapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42575764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Diagnosis and Treatment of Autoimmune Diseases by the Method of Resonance Medicine 共振医学方法在自身免疫性疾病诊断与治疗中的应用

International journal of immunology and immunotherapy Pub Date : 2022-06-30 DOI: 10.23937/2378-3672/1410064

Viktorm Praznikov

引用次数: 0

Petechial Rash and Thrombocytopenia after the Booster Dose of Covid-19 Vaccine: A Case Report and Literature Review 新冠肺炎疫苗加强剂接种后的皮疹和血小板减少症：病例报告和文献综述

International journal of immunology and immunotherapy Pub Date : 2022-04-25 DOI: 10.23937/2378-3672/1410063

Chowdhury Selia, Chowdhury Samia, Chowdhury Nurjahan Shipa, Patousis Athanasios, Gerothanasi Anna, Patousis Panagiotis

引用次数: 0

Immuno-Therapy in Lung Cancer - How Does Immuno-therapy for Lung Cancer Change Patients' Vision? 肺癌免疫治疗-肺癌免疫治疗如何改变患者的视力?

International journal of immunology and immunotherapy Pub Date : 2022-03-23 DOI: 10.23937/2378-3672/1410062

Dahal Tshetiz

引用次数: 1

Expression Pattern of IL-6 and Interferon Gamma (IFN-γ) from Chronic Hepatitis B Genotype D Patients from Nepal 尼泊尔慢性乙型肝炎基因D型患者IL-6和干扰素γ的表达模式

International journal of immunology and immunotherapy Pub Date : 2022-01-09 DOI: 10.23937/2378-3672/1410061

S. Smita, Sharma Mukunda, Manandhar Krishna Das

引用次数: 0